Alkermes PLC (ALKS, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients. Alkermes PLC has a market cap of $5.07 billion; its shares were traded at around $32.54 with and P/S ratio of 4.73.
For the last quarter Alkermes PLC reported a revenue of $315.8 million, compared with the revenue of $275.4 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $1.1 billion, an increase of 21.1% from last year. For the last five years Alkermes PLC had an average revenue growth rate of 13.8% a year.
The reported loss per diluted share was 90 cents for the year, compared with the loss per share of $0.21 in the previous year. The Alkermes PLC had an operating margin of -9.06%, compared with the operating margin of -16.37% a year before. The 10-year historical median operating margin of Alkermes PLC is -19.51%. The profitability rank of the company is 6 (out of 10).
At the current stock price of $32.54, Alkermes PLC is traded at 35.4% discount to its historical median P/S valuation band of $50.41. The P/S ratio of the stock is 4.73, while the historical median P/S ratio is 7.40. The stock lost 48.96% during the past 12 months.
Directors and Officers Recent Trades:
- Director Paul J Mitchell sold 1,000 shares of ALKS stock on 02/01/2019 at the average price of $32.73. The price of the stock has decreased by 0.58% since.
For the complete 20-year historical financial data of ALKS, click here.
